|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
20-22 Wenlock Road, London, London N1 7GU, GB
|
|
Autolomous is a company founded by Cell and Gene Therapy (CGT)- and software development experts, who have combined their skills to deliver elegant, seamless and agile solutions to the CGT sector. Autolomous will deliver the digital solutions necessary for CGT to achieve scalability, allowing more patients to benefit from these life changing therapies. The company is creating a portfolio of software solutions (AutoloMATE-solution platform), from electronic Batch Manufacturing Records (eBMR) to enabling the scheduling of the patient blood collections at hospital; the transport of those cells to the manufacturing facilities; enhancing traceability throughout the manufacturing process; supporting compliance with current and future regulatory requirements; expediting the drug product release; and the scheduled delivery of the patient-specific medicine to the hospital. Our software will enable increased automation of these processes, reducing the risk of errors and ensuring that the correct product is returned to the right patient. AutoloMATE has been architected with agility, flexibility and adaptability in mind both for our customers for customization but also for our partners to integrate with our platform to create an end-to-end digital ecosystem.
We’re looking for new team members. Are you a forward-thinking-digitally-minded individual? Do you want to be part of a meaningful and value-orientated company? Get in touch!
|
Autolomous Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Autolomous email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Autolomous customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.